Rethinking Immune-Checkpoint Therapy: Tailored Approaches Emerge
The advent of anti-PD-L1 antibodies has revolutionized the landscape of cancer therapy, particularly reshaping treatment paradigms for patients diagnosed with early-stage malignancies. Historically, these immune...
















